Improve the Success of Novel Immunotherapies
In Checkpoint Therapy, processes such as lead discovery, bioprocess optimization, and biomarker development for the clinic are all made more complex by the functional interactions stemming from the patient immune cells.
“The ability to easily perform single-cell proteomics provides a way to understand the complexity of the cellular response to immunotherapy and then to design and test new therapies to enhance efficacy.”
Detect the small potent cell subsets that make the difference
Discover critical differences and mechanisms in therapies that engage T cells and the tumor microenvironment.
Optimize potency in control and new combination therapies
Uncover the T-cell mechanisms of agonists used in combination with re-engineered cell therapies.
Correlate data with response to predict clinical outcome
Uniquely stratify patient response in solid tumor based on TIL polyfunction.